Inactive Ingredient Search for Approved Drug Products

• Share
• Tweet
• Linkedin
• Pin it
• More sharing options
  • Linkedin
  • Pin it
• Email
• Print

You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with E

	Quarter	Inactive Ingredient	Route of Administration	Dosage Form	Maximum Potency per unit dose	Maximum Daily Exposure	Status
2207	Q3 2021	ERYTHROSINE SODIUM ANHYDROUS	ORAL	CAPSULE	0.42 mg		Correction
2207	Q4 2021	ERYTHROSINE SODIUM ANHYDROUS	ORAL	CAPSULE	0.01 mg		Correction
2088	Q3 2021	EDETATE DISODIUM	INTRACARDIAC	INJECTION	0.02 %w/v		MDE Replacement
2088	Q4 2021	EDETATE DISODIUM	INTRACARDIAC	INJECTION		1.8 mg	MDE Replacement
2146	Q3 2021	EDETATE DISODIUM	TOPICAL	GEL	0.17 %w/w		MDE Replacement
2146	Q4 2021	EDETATE DISODIUM	TOPICAL	GEL		1 mg	MDE Replacement
2156	Q3 2021	EDETATE DISODIUM	VAGINAL	CREAM	0.05 %w/w		MDE Replacement
2156	Q4 2021	EDETATE DISODIUM	VAGINAL	CREAM		2 mg	MDE Replacement
2192	Q3 2021	EGG PHOSPHOLIPIDS	INTRAVENOUS	INJECTION, EMULSION	14.46 %w/v		MDE Replacement
2192	Q4 2021	EGG PHOSPHOLIPIDS	INTRAVENOUS	INJECTION, EMULSION		2610 mg	MDE Replacement
2261	Q3 2021	ETHYLCELLULOSE (10 MPA.S)	ORAL	CAPSULE, DELAYED RELEASE	11.79 mg		MDE Replacement
2261	Q4 2021	ETHYLCELLULOSE (10 MPA.S)	ORAL	CAPSULE, DELAYED RELEASE		11.79 mg	MDE Replacement
2262	Q3 2021	ETHYLCELLULOSE (10 MPA.S)	ORAL	CAPSULE, EXTENDED RELEASE	175.40 mg		MDE Replacement
2262	Q4 2021	ETHYLCELLULOSE (10 MPA.S)	ORAL	CAPSULE, EXTENDED RELEASE		270 mg	MDE Replacement
2286	Q3 2021	ETHYLCELLULOSE (50 MPA.S)	ORAL	CAPSULE	69.97 mg		MDE Replacement
2286	Q4 2021	ETHYLCELLULOSE (50 MPA.S)	ORAL	CAPSULE		139.94 mg	MDE Replacement
2120	Q4 2021	EDETATE DISODIUM	ORAL	SOLUTION/ DROPS	1.00 mg/ 1.00 ml		Deletion

 

 

FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly

Data Through: September 30, 2021
Database Last Updated: October 21, 2021